Eliem Therapeutics (ELYM) Stock Forecast, Price Target & Predictions
ELYM Stock Forecast
Eliem Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ELYM Analyst Ratings
According to 2 Wall Street analysts, Eliem Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ELYM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 26, 2022 | Guggenheim | Neutral | Downgrade |
Eliem Therapeutics's last stock rating was published by SVB Leerink on Aug 16, 2022. The company gave ELYM a "Outperform" rating, the same as its previous rate.
Eliem Therapeutics Financial Forecast
Eliem Therapeutics Revenue Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| Revenue | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| # Analysts | - | - |
| Surprise % | - | - |
Eliem Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELYM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Eliem Therapeutics EBITDA Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EBITDA | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
undefined analysts predict ELYM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Eliem Therapeutics's previous annual EBITDA (undefined) of $NaN.
Eliem Therapeutics Net Income Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| Net Income | - | - |
| Avg Forecast | $46.78M | $40.75M |
| High Forecast | $46.78M | $40.75M |
| Low Forecast | $46.78M | $40.75M |
| Surprise % | - | - |
Eliem Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELYM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Eliem Therapeutics SG&A Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| SG&A | - | - |
| Avg Forecast | - | - |
| High Forecast | - | - |
| Low Forecast | - | - |
| Surprise % | - | - |
Eliem Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELYM last annual SG&A of $NaN (undefined).
Eliem Therapeutics EPS Forecast
| Sep 24 | Jun 24 | |
|---|---|---|
| # Analysts | - | - |
| EPS | - | - |
| Avg Forecast | $1.54 | $1.34 |
| High Forecast | $1.54 | $1.34 |
| Low Forecast | $1.54 | $1.34 |
| Surprise % | - | - |
According to undefined Wall Street analysts, Eliem Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELYM previous annual EPS of $NaN (undefined).
Eliem Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |